Opinion
Video
Author(s):
Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.
Video content above is prompted by the following:
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
2 Commerce Drive
Cranbury, NJ 08512